Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy

Journal of Clinical Pharmacology

Volumn 52, Issue 6, 2012, Pages 789-797

  Riesmeyer, Jeffrey S ^a   Salazar, Daniel E ^b   Weerakkody, Govinda J ^a   Ni, Lan ^a   Wrishko, Rebecca E ^a   Ernest, C Steven ^a   Luo, Junxiang ^a   Li, Ying G ^a   Small, David S ^a   Rohatagi, Shashank ^b   MacIas, William L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

active metabolite exposure; low body weight and elderly; post hoc analysis; prasugrel; substudy

Indexed keywords

CLOPIDOGREL; DRUG METABOLITE; PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RISK ASSESSMENT; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; BIOTRANSFORMATION; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MODELS, BIOLOGICAL; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRODRUGS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SEVERITY OF ILLNESS INDEX; THIOPHENES; THROMBOSIS;

EID: 84861820192     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011406280     Document Type: Article

References (27)

1. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005 ; 31: 184-194
2. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 ; 31: 174-183
3. Geiger J, Brich J, Hönig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2007-2011
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357: 2001-2015
5. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 ; 29: 21-30
6. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27: 1166-1173
7. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747 LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 ; 111: 3366-3373
8. Wrishko RE, Ernest CS, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009 ; 49: 984-998
9. Ernest CS, Heathman MA, Wrishko RE. Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis. J Clin Pharmacol. 2009 ; 49: 973-983
10. Parsippany, NJ: Daiichi Sankyo, Inc and Eli Lilly and Company ;
11. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 ; 152: 627-635
12. Ernest CS, Small DS, Rohatagi S, et al. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008 ; 35: 593-618
13. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109: 3171-3175
14. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008 ; 51: 2028-2033
15. ClinicalStudyResults.org. Study TAAW for prasugrel. http://www. clinicalstudyresults.org/drugdetails/?inn-name-id=1129&sort=c. company-name&page=3&drug-id=8940. Accessed September 30, 2009.
16. ClinicalStudyResults.org. Study TAAE for prasugrel. http://www. clinicalstudyresults.org/drugdetails/?company-id=8&inn-name-id= 1129&sort=c.company-name&page=1&drug-id=8921. Accessed August 30, 2010.
17. ClinicalStudyResults.org. Study TAAU for prasugrel. http://www. clinicalstudyresults.org/drugdetails/?company-id=8&inn-name-id= 1129&sort=c.company-name&page=2&drug-id=8938. Accessed August 30, 2010.
18. Effient (prasugrel) [package insert]. Parsippany, NJ: Daiichi Sankyo, Ltd and Eli Lilly and Company; 2009. http://pi.lilly.com/us/effient.pdf. Accessed September 4, 2009.
19. Efient (prasugrel). Summary of product characteristics. Parsippany, NJ: Daiichi Sankyo, Inc and Eli Lilly and Company. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Efient/emea-combined-h984en.pdf. Accessed September 4, 2009.
20. Parsippany, NJ: Daiichi Sankyo, Inc and Eli Lilly and Company ;
21. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007 ; 25: 357-374
22. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000 ; 129: 1439-1446
23. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 ; 119: 2553-2560
24. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 ; 360: 354-362
25. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009 ; 30: 1744-1752
26. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005 ; 294: 3108-3116
27. Sinnaeve PR, Huang Y, Bogaerts K, et al. Age outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J. 2006 ; 152: 684.e1 - e9